SCHEMBL2069697

SCHEMBL2069697

Nc1ccnc(-c2ccco2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
APAF1 O14727 1/20 0.52
NPC1 O15118 1/20 0.52
NSD2 O96028 1/20 0.52
RAB9A P51151 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
SAE1 Q9UBE0 1/20 0.52
UBA2 Q9UBT2 1/20 0.52
ADORA2A P29274 4/20 0.50
ADORA1 P30542 4/20 0.50
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
ADORA2B P29275 2/20 0.47
CYP19A1 P11511 1/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27661591 0.83 KDM4E (0.60) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL5259444 0.79 POLB (0.65) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL27651185 0.77 KDM4E (0.47) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL25271063 0.77 POLB (0.52) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL25719744 0.77 NPC1 (0.52) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL11831197 0.77 POLB (0.52) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL27754726 0.76 HSP90AA1 (0.42) KDM4EKMT2AMEN1
SCHEMBL5017694 0.76 ADORA2A (0.56) POLBAPAF1NPC1NSD2RAB9A
SCHEMBL1921676 0.74 NOS2 (0.44) KDM4EALOX15TDP1L3MBTL1
SCHEMBL28135935 0.74 KDM4E (0.58) POLBAPAF1NPC1NSD2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422271-B2 Pyrimidine compounds as tuberculosis inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-08-23 US disclosed
US-20140249137-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-04 US disclosed
US-20110053916-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-03 US disclosed
US-3957766-A BACTERIOSTATS, BACTERICIDES BOEHRINGER MANNHEIM G.M.B.H. (DT) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249137-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS TYMS, TYMP, DPYD POLB 94/4885APAF1 2657/4885NPC1 1434/4885
US-20110053916-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS TYMS, TYMP, DPYD POLB 94/4885APAF1 2657/4885NPC1 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.